Trial reportOphthalmology2009
Low-dose aspirin and medical record-confirmed age-related macular degeneration in a randomized trial of women.
Trial report in Ophthalmology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Pooled it
- Association Between Aspirin Usage and Age-Related Macular Degeneration: An Updated Systematic Review and Meta-analysis.Frontiers in pharmacology · 2022Pooled it
- Pooled it
- Trial
- Effect of Vitamin D and ω-3 Fatty Acid Supplementation on Risk of Age-Related Macular Degeneration: An Ancillary Study of the VITAL Randomized Clinical Trial.JAMA ophthalmology · 2020Trial
- The Association of Aspirin Use with Age-Related Macular Degeneration Progression in the Age-Related Eye Disease Studies: Age-Related Eye Disease Study 2 Report No. 20.Ophthalmology · 2019Trial
- Causal relationship between aspirin use and age-related macular degeneration.Eye (London, England) · 2026Article
- Prostanoid signaling in retinal vascular diseases.Prostaglandins & other lipid mediators · 2024Review
- ASCEND-Eye: Rationale, design and baseline characteristics for a sub-study of the ASCEND randomised trial, exploring the effects of aspirin and omega-3 fatty acids on diabetic retinopathy and age-related macular degeneration.Contemporary clinical trials communications · 2023Article
- Medication Trends for Age-Related Macular Degeneration.International journal of molecular sciences · 2021Review
- Non-steroidal Anti-inflammatory Drug Use and Risk of Age-Related Macular Degeneration in the California Teachers Study.Drugs & aging · 2021Article
- Age-Related Macular Degeneration: Epidemiology and Clinical Aspects.Advances in experimental medicine and biology · 2021Article
- Article
- Baseline characteristics and age-related macular degeneration in participants of the "ASPirin in Reducing Events in the Elderly" (ASPREE)-AMD trial.Contemporary clinical trials communications · 2020Article
- Age-related macular degeneration in a randomized controlled trial of low-dose aspirin: Rationale and study design of the ASPREE-AMD study.Contemporary clinical trials communications · 2017Article
- Age-related macular degeneration in patients with uveitis.The British journal of ophthalmology · 2017Article
- Does the use of acetylsalicylic acid have an influence on our vision?Clinical interventions in aging · 2016Review
- Aspirin and age related macular degeneration; the possible relationship.Medical hypothesis, discovery & innovation ophthalmology journal · 2013Review
- Article
- Lipid metabolites in the pathogenesis and treatment of neovascular eye disease.The British journal of ophthalmology · 2011Review
Corrections and comments
- Commented on by
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveTo test whether alternate-day low-dose aspirin affects incidence of age-related macular degeneration (AMD) in a large-scale randomized trial of women.
designRandomized, double-masked, placebo-controlled trial.
participantsThirty-nine thousand eight hundred seventy-six healthy female health professionals aged 45 years or older.
interventionParticipants were assigned randomly to receive either 100 mg aspirin on alternate days or placebo and were followed up for the presence of AMD for an average of 10 years.
main outcome measuresIncident AMD responsible for a reduction in best-corrected visual acuity to 20/30 or worse based on self-report confirmed by medical record review.
resultsAfter 10 years of treatment and follow-up, there were 111 cases of AMD in the aspirin group and 134 cases in the placebo group (hazard ratio, 0.82; 95% confidence interval, 0.64-1.06).
conclusionsIn a large-scale randomized trial of female health professionals with 10 years of treatment and follow-up, low-dose aspirin had no large beneficial or harmful effect on risk of AMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.